Literature DB >> 24521738

An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis.

G P R Clunie1, A Ginawi, P O'Conner, P W Bearcroft, S J Garber, S Bhagat, A Grainger, J S H Gaston.   

Abstract

Entities:  

Keywords:  Ankylosing Spondylitis; Magnetic Resonance Imaging; Treatment

Mesh：

Substances：

Year:  2014        PMID： 24521738     DOI： 10.1136/annrheumdis-2013-204938

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

Review 1.  Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?

Authors:  Gavin Clunie; Nicole Horwood
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-30       Impact factor: 5.346

2.  Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis.

Authors:  Suzanne Arends; Freke Wink; Joyce Veneberg; Reinhard Bos; Eric van Roon; Eveline van der Veer; Fiona Maas; Anneke Spoorenberg
Journal:  Br J Clin Pharmacol       Date:  2020-07-05       Impact factor: 3.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.